Trial Profile
Study for Apatinib combined with Icotinib in patients with slow progression of non-small cell lung cancer after failure of Icotinib therapy
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 22 Oct 2018
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary) ; Icotinib
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 22 Oct 2018 New trial record